🇺🇸 FDA
Patent

US 8318666

Use of leptin to treat metabolic abnormalities associated with lipoatrophy

granted A61KA61K31/155A61K31/426

Quick answer

US patent 8318666 (Use of leptin to treat metabolic abnormalities associated with lipoatrophy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Nov 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61K, A61K31/155, A61K31/426, A61K38/2264, A61K45/06